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Abstract
Background—To reduce the risk of adjustment problems associated with Hematopoietic Stem
Cell Transplant (HSCT) for adolescents/young adults (AYA), we examined efficacy of a
therapeutic music video (TMV) intervention delivered during the acute phase of HSCT to: (a)
increase protective factors of spiritual perspective, social integration, family environment,
courageous coping, and hope-derived meaning; (b) decrease risk factors of illness-related distress
and defensive coping; and (c) increase outcomes of self-transcendence and resilience.
Methods—A multi-site, randomized controlled trial (COG-ANUR0631) conducted at 8
Children’s Oncology Group sites involving 113 AYA aged 11–24 years undergoing myeloablative
HSCT. Participants, randomized to the TMV or low-dose control (audiobooks) group, completed 6
sessions over 3 weeks with a board-certified music therapist. Variables were based on Haase’s
Resilience in Illness Model. Participants completed measures related to latent variables of illness-
related distress, social integration, spiritual perspective, family environment, coping, hope-derived
meaning and resilience at baseline (T1), post-intervention (T2), and 100-days post-transplant (T3).
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Results—At T2, the TMV group reported significantly better courageous coping (ES=0.505;
P=0.030). At T3, the TMV group reported significantly better social integration (ES=0.543; P=.
028) and family environment (ES=0.663; P=0.008), as well as moderate non-significant effect
sizes for spiritual perspective (E=0.450; P=0.071) and self-transcendence (ES=0.424; P=0.088).
Conclusion—The TMV intervention improves positive health outcomes of courageous coping,
social integration, and family environment during a high risk cancer treatment. We recommend the
TMV be examined in a broader population of AYA with high risk cancers.
INTRODUCTION
High distress experienced by adolescents/young adults (AYA) during hematopoietic stem
cell transplant (HSCT) contributes to persistent defensive coping and poor social and family
relationships during acute treatment – placing AYA at additional risk for adjustment
problems in survivorship.1–4 Conversely, protective factors may buffer adverse cancer
effects and assist AYA to positively adjust during and after treatment.5,6 Some AYA
experience positive growth following treatment, while others do not; the absence of
predictive models describing AYA post-HSCT adjustment make it difficult, if not
impossible, to identify who is at-risk requiring additional support or intervention.7–9
Effective coping strategies and psychosocial support during HSCT are key to improving
adjustment and quality of survival;10–12 however, theoretically-derived interventions
specifically designed for AYA are few and tenuous.13–15 Recognizing that HSCT usually
induces high symptom distress that is difficult to manage and in the absence of predictive
models to identify AYA at risk, this paper reports efficacy of the Therapeutic Music Video
(TMV) intervention (COG ANUR0631), as a preventive intervention for AYA undergoing
HSCT.
Our study was guided by the Resilience in Illness Model (RIM, Figure 1).6,16 This strengths-
based, positive health model elucidates pathways by which risk and protective factors
influence AYA adjustment to difficult life circumstances. RIM was developed and evaluated
through a series of mixed methods studies;17,18 exploratory and confirmatory evaluations in
AYA with cancer indicate a well-fitting measurement model and the full model predicts
proximal and distal outcomes (R2 = 0.62 to 0.72).17,18 For this study, we hypothesized the
TMV would: (a) increase protective factors of spiritual perspective, social integration,
family environment (adaptability, cohesion, communication), courageous coping, and hope-
derived meaning (primary proximal outcomes), (b) decrease risk factors of illness-related
distress (uncertainty in illness, symptom-related distress) and defensive coping (secondary
proximal outcomes), and (c) increase outcomes of self-transcendence and resilience
(secondary distal outcomes).
Robb’s Contextual Support Model of Music Therapy (CSM-MT) guided selection of TMV
intervention components. Grounded in motivational and developmental coping theory, the
CSM-MT describes how music interventions create predictability, autonomy support, and
relationship support to promote positive health outcomes.19 The CSM-MT has informed
development of several music therapy interventions to improve coping and manage
distress.19–21 Unlike distraction-based, passive music listening interventions, the TMV uses
music to provide (a) predictability through clearly defined goals and structured, preferred
music, (b) autonomy support through AYA-directed choices about music, lyric writing,
video content, and involvement of others, and (c) relationship building through a non-
threatening, creative activity to help AYA explore, identify, and express what is important to
them (Table 1).15,22–25 As a music therapy intervention, TMV components are delivered
within a therapeutic relationship by a credentialed professional.26
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TMV intervention components directly address RIM protective factors by encouraging AYA
to actively engage with their environment (courageous coping); reflect on their experiences
and identify what is important (spiritual perspective, social integration, family environment);
identify future hopes/desires (hope-derived meaning); involve family, peers, and/or
healthcare providers in their project as desired (social integration, family environment); and
communicate ideas to others (social integration, family environment).
METHODS
Participants
After scientific and institutional review board approvals, transplant staff introduced the
study to potentially eligible AYA. Study personnel then provided interested AYA with
detailed information before obtaining informed consent/assent. Participants were recruited
from 8 Children’s Oncology Group (COG) institutions, including 3 with affiliated adult
transplant programs. Eligibility criteria included: AYA aged 11 to 24 years; undergoing a
myeloablative HSCT for cancer; and ability to read and speak English. Exclusion criteria
included: cancer diagnosis not common to AYA; physician determination of cognitive
impairments precluding ability to complete measures; and being married and/or having
children.
Procedures
Participants completed baseline measures (T1) via a secure web-based server within 30 days
of HSCT unit admission and were immediately randomized to the TMV or low-dose, control
group using 24 strata (8 sites individually stratified by 3 age groups: 11–14, 15–18, 19–24).
Then, both groups received six sessions, 2 per week during the acute HSCT phase. Follow-
up evaluations occurred after session 6 (T2) and 100-days post-transplant (T3). Data
collectors, masked to group assignment, monitored data collection to answer questions and
ensure a quiet environment. Treatment and evaluation fidelity strategies included:
standardized training; manualized, audio-recorded protocols for quality assurance (QA)
monitoring; computerized QA checklists; and bi-monthly intervention and evaluation team
conference calls.27,28
Study Conditions
Both study conditions, delivered by a consistent board-certified music therapist, provided
the same opportunities for attention. External QA monitoring was done to assure therapists
consistently followed protocol for assigned study conditions.
TMV content was designed to accommodate acute phase HSCT demands (Table 1). Most
cognitive and active intervention components occurred in sessions 1–3, during the first two
weeks of transplant when AYA usually experience less symptom distress. Sessions 4–6 had
fewer active components, and provided activity-level flexibility. Sessions 1–3 included
singing, brainstorming, lyric writing, discussion, and song recording. Sessions 4 and 5 used
AYA-developed song lyrics as a foundation for selecting visual video content (e.g., artwork,
photographs) through storyboarding and discussion. In session 6, participants viewed their
completed video and had the option of a “Video Premier” with family, friends, and/or
hospital staff.
Control group AYA chose from 15 audiobooks selected by a librarian with expertise in
AYA literature. The books were age-appropriate, fiction and non-fiction, and balanced in
gender and ethnic diversity. During sessions, AYA had the opportunity to listen to and/or
discuss the book content; between sessions, AYA could listen to and exchange books as
desired.
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Measures
RIM variables, calculated based on a latent variable ANCOVA model performed with
structural equation modeling (SEM), were used to evaluate outcomes. Measures supporting
RIM were selected and evaluated using mixed methods approaches.6,16,18 Table 2
summarizes each measure’s structural and psychometric properties. Cronbach’s alpha
coefficients from T1 data ranged from .75 to .91 (.60–.94 for subscales). More
comprehensive measure descriptions are available in exploratory and confirmatory RIM
evaluation reports.6,16
Statistical Analysis
Sample size calculation was based on an anticipated 25% mortality rate for HSCT across all
transplant types within the first 100 days.29 Therefore, target recruitment was 175 AYA to
accrue 130 AYA at T3, providing 65 AYA in each group and power of .80 for a two-sided t
test, with alpha 0.05, for detecting differences between group means of 0.50 standard
deviation. Because the number of eligible AYA and the recruitment rate were lower than
expected during the grant period, we were unable to reach our target sample.
MPLUS software, version 6.12, was used for analysis. We tested efficacy using a structural
equation modeling approach, estimating latent-variable ANCOVA models to account for
measurement error and to reduce the number of comparisons.30 Specifically, the randomized
groups were compared on latent variables at T2 adjusted for latent variables at T1, and on
latent variables at T3 adjusted for latent variables at T1, using scale scores as observed
indicators of the latent variables as specified in the RIM measurement model. To provide
meaningful interpretations, the effect size for the intervention effect on the T2 and T3 latent
variables was computed by converting the t value of the intervention coefficients supplied
by MPLUS output to a Cohen standardized difference between means.31
We tested interaction terms between the intervention effect and baseline (e.g., demographic,
treatment-related, and disease-related) covariates. All interaction terms were non-significant
and therefore not included in the final models. We tested whether the two randomized arms
differed on any baseline characteristics; if significant at a liberal alpha of 0.20 (to ensure
conservative adjustment), the covariate was included as a predictor to control for its
potentially confounding impact on intervention effect estimations.
We did not adjust alpha for multiple comparisons of outcomes because the use of latent
ANCOVA models already reduced the number of comparisons to a select set of latent
variables. Furthermore, the latent-variable dependent variables in the ANCOVA tap into
unique conceptual areas that represent important pre-planned outcomes from our published
RIM model.6,16 An intent-to-treat analysis was performed in which all available
questionnaire data at T2 and T3 were used and participants were analyzed according to their
assigned group regardless of their degree of adherence to the protocols for the intervention
and low-dose control groups.
RESULTS
Figure 2 summarizes study accrual, intervention delivery, and data collection. The groups
were statistically similar on demographic and treatment variables (Table 3) with one
exception; the TMV group reported significantly more religious activity participation than
the control group (58.6% vs. 37.0%, P=0.02). Therefore, this binary religious activity
variable was adjusted in the latent ANCOVA models (Table 4). These models were used to
compare the two groups on T2 or T3 latent outcome variables, while adjusting for T1 latent
outcome variable and the observed religious activity variable.
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We assessed the attrition rate and found attrition at T2 and T3 were not significantly
different for the two groups. Nor were T3 completers significantly different from T3 non-
completers on baseline demographic variables.
To guide the reader through results, we describe in detail the T2 ANCOVA comparison for
the illness-related distress factor (Table 4, Row 1). Illness-related distress was measured in
the latent ANCOVA models with two indicators at T1 and at T2. As shown in Table 2,
illness-related distress indicators were the symptom distress and uncertainty in illness scale
scores. At T2, 36 TMV and 40 control participants had data for the illness-related distress
factor, and the MPLUS t value for the latent ANCOVA was equal to −0.686. This t value
was equivalent to a Cohen effect size measure of −0.160 standard deviations. A negative
sign for the t value and ES implies that the T2 adjusted mean for illness-related distress was
lower for the TMV group than the control group; however, the difference was not significant
(P=0.493).
At T2, the adjusted mean for the courageous coping factor was significantly greater for the
TMV group compared to the control group, after adjusting for T1 latent courageous coping
and religious activity. The effect size for this significant difference (ES=0.505; P=0.030)
was of moderate magnitude according to the Cohen criteria in which .20 is low, .50 is
moderate, and greater than .80 is large.32 At T3, the TMV group reported significantly better
social integration (P=0.028) and family environment (P=0.008) than the control group. The
effect sizes were moderate for both of these differences (0.543 and 0.663, respectively).
DISCUSSION
The TMV significantly improved courageous coping immediately post-intervention and
significantly improved social integration and family environment at 100-days post-
transplant, with additional moderate but non-significant effect sizes for spiritual perspective
and self-transcendence. These findings support RIM sensitivity to detect group differences,
and TMV efficacy to promote positive growth of AYA in the areas of courageous coping,
social integration, and family environment during a high risk, high intensity cancer
treatment.
The effect size for courageous coping was moderate, indicating that TMV participants
increased their use of positive coping strategies to a greater extent than control participants.
Concurrently, we found no change in the use of defensive coping strategies. This finding is
important since individuals are more likely to use defensive coping strategies during life-
threatening or high distress situations like HSCT.7 Although initially adaptive, prolonged
use of defensive coping strategies is associated with more risk-taking behaviors, and less
positive adjustment; movement toward positive forms of coping is desirable.33 The TMV
helped AYA use positive coping strategies during treatment, which is associated with better
long-term adjustment in cancer survivors.8,17
Although engaging in meaningful activities can sometimes alleviate symptom distress, we
found no significant effects for illness-related distress immediately or 100-days post-
transplant. Given high levels of HCST-related symptom distress and uncertainty, patients
may benefit from interventions that offer physiologically-based relaxation and/or uncertainty
management strategies to reduce these risk factors. Significant effects were found 100-days
post-transplant for social integration and family environment and moderate but non-
significant effect sizes were found for spiritual perspective and self-transcendence. The
TMV was designed to help AYA identify and reflect on what is important to them through
lyric writing and selection of visual images. Qualitative analysis of AYA lyrics and video
images revealed that AYA were identifying peers (i.e., social integration), family members
Robb et al. Page 5
Cancer. Author manuscript; available in PMC 2015 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(i.e., family environment), and faith/spirituality (i.e., spiritual perspective) as important
sources of support.34 At T2, AYA had just viewed their video and may not have had
adequate time to share, reflect on, and fully integrate the meaningfulness of their video,
which may explain why positive change for these measures did not occur until T3.35,36
At T3 we saw notable, but non-significant improvement in the secondary distal outcome
self-transcendence. Time for self-reflection is essential for AYA to derive meaning from and
integrate their cancer experience in order to transcend or move beyond their cancer
treatment.35–37 One-hundred days may not be adequate time to fully reflect on and integrate
what AYA explored through their videos. Unknown is whether, having “survived” the
transplant, additional time for self-reflection would result in additional gains.
Timelines for intervention delivery/completion offer additional evidence supporting TMV
clinical feasibility for AYA during HSCT. Despite high level HSCT-related symptom
distress, 75% of TMV participants were able to complete the intervention within 30 days,
which was +/− 9 days within the proposed three week delivery timeframe. The remaining
25% were successful, but required more time to complete the intervention; reasons for
delayed sessions included symptom distress, intensive care unit admissions, and/or tandem
transplants requiring multiple admissions. Our ability to flexibly manage intervention
delivery in response to AYA symptom distress, without jeopardizing treatment integrity,
was monitored through rigorous quality assurance strategies.27 Post-intervention interviews
revealed AYA and parent appreciation for scheduling flexibility that honored AYA needs.23
There are four study limitations. First, risk for bias in condition delivery increased because
music therapists delivered both conditions to control for individual therapist qualities and
mask data collectors to AYA group assignment. This risk was mitigated through stringent
treatment fidelity procedures across conditions.27 Second, the study was underpowered.
Instead of the planned 80% power, we had 57% power to detect a medium effect size (0.50)
at T2 using samples of 36 and 40 for intervention and control groups, respectively, and 52%
at T3 using samples of 31 and 36. Therefore, potential for type II error was greater than
initially planned. Third, missing data due to attrition at T2 or T3 may have contributed to
biased intervention effect estimates. Fourth, no formal cost analysis was done; however,
services from board-certified music therapists are increasingly considered standard care in
pediatric hospitals.38,39
In summary, few interventions target the unique psychosocial needs of AYA with cancer.
The RIM was a useful guide for TMV evaluation, and TMV was beneficial for improving
positive coping, social integration, and family environment for AYA undergoing HSCT.
Future studies examining distal outcomes beyond 100-days post-HSCT would help
determine whether additional time would improve observed gains in self-transcendence. As
part of a larger trial, we are evaluating the TMV in a broader population of AYA with high
risk cancers to inform intervention translation and uptake.
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Figure 1.
Exploratory RIM guiding the study.
Reprint permission: Haase JE, Kintner EK, Monahan PO, Robb SL. The resilience in illness
model, Part 1: exploratory evaluation in adolescents and young adults with cancer. Cancer
Nurs. 2013:March 20.
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Figure 2.
CONSORT diagram for trial accrual, intervention delivery, and data collection.
Note: The death rate did not differ significantly between the two arms (two-sided Fisher
exact test, p = .21).
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Table 1
TMV Intervention: Summary of Contextual Support and Intervention Content
Elements of Contextual Support from
CSM-MT
Summary of Intervention Content by Sessiona
Week Session TMV Intervention Content
Structure
• Familiar, predictable music
• Song Scripts
• Storyboards
• Leveled Involvement
Autonomy Support
• AYA-Directed
• Choices (music, lyrics, visual images, vocalists,
involving others)
• Quality product
Relationship Support
• Music to communicate unspoken thoughts, feelings,
dreams for future
• AYA-Centered
• Therapist support
• Family, peer, healthcare provider involvement
1 1 - Learn how to use a songwriting script
- Select music for project (i.e., offered 10 songs
from 5 music genres)b
- Brainstorm ideas for lyric/video content (i.e.,
what is important to AYA)
1 2 - Write lyrics to a familiar song using a
songwriting script
- Discuss lyrics and what is important to AYA
- Sing/practice song with CD accompaniment track
- Select who will sing on the song recording
2 3 - Sing/rehearse completed song
- Discuss AYA thoughts about/reflections on video
project
- Digitally record vocal soundtrack for video
- Listen to AYA vocals mixed with
accompaniment trackb
2 4 - Begin storyboard process (i.e., select visual
images to go with song lyrics)
- Listen to completed song/discuss visual images –
memories/importance
- Digital camera available during hospitalization
3 5 - Gather visual images and/or take pictures
- Complete storyboard
- Listen to completed song/discuss visual images -
memories/importance
3 6 - Private viewing of music DVD
- Optional “Video Premiere” (i.e., AYA invites
other to view)
AYA = adolescents/young adults; CD= compact disc; DVD = digital video disk; TMV = therapeutic music video.
aSessions facilitated by board-certified music therapists.
bCD accompaniment purchased for each music video project. Music selections available upon request.
Reprint permission: Docherty SL, Robb SL, Phillips-Salimi C, et al. Parental perspectives on a behavioral health music intervention for adolescent/
young adult resilience during cancer treatment: report from the children's oncology group. J Adolesc Health. Feb 2013;52(2):170–178.
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